COMPARISON
Bacitracin vs Vancomycin
3 attributes held for at least one of the two. 2 differ. Each value carries the register it came from and the date that register was read.
Answer
Bacitracin is authorised or registered in 8 and Vancomycin in 9 of the 10 registers read. Bacitracin: No trial states a phase. Vancomycin: highest phase Phase 4 (after approval). 6 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Bacitracin | Vancomycin | |
|---|---|---|
| Registered trials differs | 53 clinicaltrials.gov · 2026-10-03 | 738 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA label, not an approval: health and .beyond Triple Antibiotic openfda · 2026-10-03T17:23:44.062Z | FDA-approved: Vancomycin Hydrochloride openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation | Nothing on record ema read 2026-08-31 | Nothing on record ema read 2026-08-31 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Bacitracin | placebo | Vancomycin | placebo |
|---|---|---|---|---|
| Cough | - | - | 16.1% | 12.3% |
| Headache | - | - | 5.8% | 6.4% |
| Nausea | - | - | 5.0% | 5.3% |
| Pyrexia | - | - | 5.0% | 4.4% |
| Diarrhoea | - | - | 4.7% | 4.8% |
| Vomiting | - | - | 2.3% | 5.2% |
Trial register Bacitracin: 0 placebo-controlled trials; Vancomycin: 5. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Bacitracin side effects · Vancomycin side effects
LEGAL STATUS
Approval in each country read
| Country | Bacitracin | Vancomycin | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Not on the register | Not on the register | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Status unknown | Registered | TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Authorised | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
6 registered trials include both
| NCT06992453 | Multi-omics Dissection of Gut Microbiome Engraftment During FMT NOT_YET_RECRUITING · updated 2026-04-28 |
|---|---|
| NCT04075526 | Vancomycin Powder and Dilute Povidone Iodine Lavage for Infection Prophylaxis in High Risk Total Joint Arthroplasty COMPLETED · updated 2026-02-17 |
| NCT00634166 | Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group TERMINATED · updated 2022-09-29 |
| NCT02099240 | Patients Response to Early Switch To Oral:Osteomyelitis Study TERMINATED · updated 2021-04-06 |
| NCT01628666 | Prevention of Arrhythmia Device Infection Trial (PADIT) COMPLETED · updated 2019-06-24 |
| NCT01613092 | Prevention of Arrhythmia Device Infection Trial (PADIT) COMPLETED · updated 2014-10-10 |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.